SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
Public ClinicalTrials.gov record NCT03546582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Study identification
- NCT ID
- NCT03546582
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Enrollment
- 86 participants
Conditions and interventions
Interventions
- Pembrolizumab Drug
- Stereotactic Body Radiation Therapy (SBRT) Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2018
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2029
- Last update posted
- Jan 19, 2026
2018 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center - North Campus | Tucson | Arizona | 85719 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Cleveland Clinic - Weston | Weston | Florida | 33331 | — |
| University of Louisville, James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Washington University St. Louis | St Louis | Missouri | 63110 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| University of Cincinnati Cancer Center - UC Medical Center | Cincinnati | Ohio | 45219 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Medical Center Shadyside | Pittsburgh | Pennsylvania | 15232 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03546582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03546582 live on ClinicalTrials.gov.